TSE:LEAF - MedReleaf Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$28.29 +0.47 (+1.69 %)
(As of 06/20/2018 10:38 AM ET)
Previous CloseC$27.82
Today's RangeC$28.05 - C$29.20
52-Week RangeC$7.45 - C$31.25
Volume306,087 shs
Average Volume695,802 shs
Market CapitalizationC$1.91 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MedReleaf logoMedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.

Receive LEAF News and Ratings via Email

Sign-up to receive the latest news and ratings for LEAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
SymbolTSE:LEAF
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21.65%
Return on Equity-6.38%
Return on Assets-5.47%

Miscellaneous

EmployeesN/A
Outstanding Shares99,145,000

MedReleaf (TSE:LEAF) Frequently Asked Questions

What is MedReleaf's stock symbol?

MedReleaf trades on the Toronto Stock Exchange (TSX) under the ticker symbol "LEAF."

What price target have analysts set for LEAF?

2 brokers have issued 1-year price targets for MedReleaf's shares. Their predictions range from C$20.00 to C$36.00. On average, they anticipate MedReleaf's share price to reach C$28.75 in the next year. View Analyst Ratings for MedReleaf.

Who are some of MedReleaf's key competitors?

Who are MedReleaf's key executives?

MedReleaf's management team includes the folowing people:
  • Mr. Neil J. Closner, CEO, Co-Founder & Director
  • Mr. Igor Gimelshtein, CFO & Corp. Sec.
  • Mr. Donald Courtney, Chief Operating Officer
  • Mr. Umar Syed, Sr. VP of Corp. Devel.
  • Mr. Angelo Fefekos, Vice-Pres of Clinical Affairs & Quality Compliance

Has MedReleaf been receiving favorable news coverage?

Media stories about LEAF stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MedReleaf earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 46.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of MedReleaf?

Shares of LEAF and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is MedReleaf's stock price today?

One share of LEAF stock can currently be purchased for approximately C$28.29.

How big of a company is MedReleaf?

MedReleaf has a market capitalization of C$1.91 billion.


MarketBeat Community Rating for MedReleaf (LEAF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about MedReleaf and other stocks. Vote "Outperform" if you believe LEAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LEAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.